AI assistant
Editas Medicine, Inc. — Director's Dealing 2017
Nov 21, 2017
33260_dirs_2017-11-21_564f5fe1-2730-4ca9-b1d9-c863feeb7eba.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Editas Medicine, Inc. (EDIT)
CIK: 0001650664
Period of Report: 2017-11-17
Reporting Person: Hack Andrew A. F. (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-11-17 | Common Stock | M | 5000 | $3.23 | Acquired | 5000 | Direct |
| 2017-11-17 | Common Stock | S | 5000 | $24.8146 | Disposed | 0 | Direct |
| 2017-11-20 | Common Stock | M | 5000 | $3.23 | Acquired | 5000 | Direct |
| 2017-11-20 | Common Stock | S | 5000 | $25.3464 | Disposed | 0 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-11-17 | Stock Option (right to buy) | $3.23 | M | 5000 | Disposed | 2025-07-13 | Common Stock (5000) | Direct |
| 2017-11-20 | Stock Option (right to buy) | $3.23 | M | 5000 | Disposed | 2025-07-13 | Common Stock (5000) | Direct |
Footnotes
F1: The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017.
F2: This transaction was executed in multiple trades at prices ranging from $24.68 to $25.04. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $25.04 to $25.78. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: This option was granted on July 14, 2015 and is scheduled to vest over four years with 25% of the shares having vested on July 1, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through July 1, 2019.